top of page

Gene Therapy for Huntington's Disease: Everything We've Covered

17 hours ago
3 min read

Huntington's disease has no treatment that slows it down. It is caused by a single inherited gene, which makes it an obvious target for gene therapy, and uniQure's AMT-130 has become the first candidate to reach the FDA with long-term data behind it. This page collects everything Gene Tech Times has covered on that story, in order.


Gene Tech Times guide cover reading Gene Therapy for Huntington's Disease, everything we have covered

What the disease is

Huntington's is caused by a repeat expansion in the HTT gene. Everyone carries HTT, but in Huntington's one copy has too many repeats of a three-letter DNA sequence, and the protein it makes becomes toxic to brain cells. Symptoms usually begin between ages 30 and 50: involuntary movements, difficulty with thinking and planning, and changes in mood and behaviour. The disease is inherited in an autosomal dominant pattern, so a child of an affected parent has a 50% chance of inheriting it.

Because the faulty gene is known and does damage by making something harmful rather than by failing to make something, the therapeutic goal is to lower the amount of mutant protein rather than replace a missing one.


How AMT-130 works

AMT-130 uses an AAV5 viral vector carrying a microRNA designed to lower huntingtin production. It is delivered in a one-time neurosurgical procedure directly into the striatum, a deep brain region hit early in the disease. The surgery takes several hours and is done under MRI guidance.

This is very different from a pill or an infusion. It is a single, irreversible brain operation, which is part of why the regulatory story has been complicated.


The coverage, in order


Brain illustration highlighting the striatum, where the AMT-130 gene therapy is infused

What to watch next

The decision date is May 1, 2027. Three things will decide how this is received:

  • Whether the benefit holds. The 61% figure comes from comparing treated patients with an external group of untreated patients, not a randomised control arm. That is a real limitation, and it is the main thing reviewers will scrutinise.

  • The composite score. The weakening in one measure at four years needs explaining. It may be noise in a small group, or it may be the first sign that the effect fades.

  • Whether brain surgery scales. Even a successful therapy delivered this way is limited by how many centres can perform the procedure.


Why this one matters beyond Huntington's

If AMT-130 is approved, it will be the first gene therapy for a neurodegenerative disease caused by a toxic protein. The same lower-the-bad-protein logic applies to several other conditions, which is why this programme is watched well outside the Huntington's community. Read our explainer on why AAV gene therapies raise long-term safety questions for the other side of that coin.


The bottom line

Huntington's went from having no disease-modifying option to having one under FDA review with a decision due in May 2027. The data are encouraging and genuinely limited, and both of those things are true at once.


Keep exploring with Gene Tech Times

  • Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.

  • Learn it properly: Gene Therapy 101 walks you from DNA to approved therapies in 8 animated modules with quizzes.

  • Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.

  • Read: The Life-Changing Power of Gene Therapy, real stories from the families behind the science.

As an Amazon Associate, Gene Tech Times earns from qualifying purchases.

— T.N., Gene Tech Times

Comments


Subscribe for News

bottom of page